Karolinska Development company Modus Therapeutics announces appointment of Ellen K. Donnelly, Ph.D. as CEO
(Thomson Reuters ONE) -
STOCKHOLM - APRIL 24, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV)
today announces its portfolio company Modus Therapeutics AB, a company focused
on innovative treatments for patients with sickle cell disease (SCD), has
appointed Ellen K. Donnelly, PhD, as Chief Executive Officer.
Details from the Modus announcement follow:
Dr. Donnelly joins Modus Therapeutics from Pfizer, Inc., where she has held
numerous leadership positions in Clinical Operations; Project and Portfolio
Management; and Research. Most recently she was responsible for Clinical
Operations for Pfizer's Neuroscience and Pain therapeutic area. Dr. Donnelly
also brings biotech and consulting experience to the CEO role, having worked in
positions within U.S. biotech and management consulting prior to her time at
Pfizer. Dr. Donnelly received her Ph.D. from Yale University.
Chairman of Modus Therapeutics, Björn Sjöstrand, said: "We are pleased to
welcome Dr. Donnelly as CEO and are confident her background and broad
experience in global drug development will help drive Modus Therapeutics
forward, as we continue patient recruitment in our Phase II clinical study with
sevuparin for SCD."
Dr. Donnelly added: "I am thrilled to join Modus at this important time for the
Company. SCD is a crippling disease affecting many hundreds of thousands of
patients around the world and Modus has a clear plan to address patients' pain
through both hospital and home-based treatment options. The high unmet medical
needs of SCD patients require novel therapeutic options, and I look forward to
working with patients and their families to ensure the best possible outcomes
for this disease, as we further develop sevuparin for SCD."
Viktor Drvota, Deputy CEO and Chief Investment Officer of Karolinska
Development, said: "We welcome Dr. Donnelly as CEO of Modus Therapeutics, and
are confident her extensive clinical development knowledge in the SCD field and
her broader corporate experience will be key to the Company's future success.
Modus is on track and financed to deliver data from its Phase II clinical study
in early 2018, providing the first opportunity for one of our therapeutic
company portfolio to meet an important clinical value-inflection point."
Dr. Donnelly is based in Stockholm and will take up her appointment on 25 April
2017. She succeeds Dr. Christina Herder.
For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail:jim.van.heusden(at)karolinskadevelopment.com
Viktor Drvota, Deputy CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota(at)karolinskadevelopment.com
David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev(at)citigatedr.co.uk
TO THE EDITORS
About Modus Therapeutics
Modus Therapeutics is a clinical-stage drug development company developing new
pharmaceutical therapies to restore impaired blood flow and oxygen transport in
rare diseases with large unmet medical need. The Company's most advanced
candidate, sevuparin, is currently being evaluated in a Phase II clinical trial
in sickle cell disease (SCD). Repeated painful crises in SCD, so-called vaso-
occlusive crises ("VOC"), leads to loss of vital organ function and often
significantly reduced life span. Modus Therapeutics is based in Stockholm. The
Company's major shareholders are KDev Investments AB (an investment fund jointly
owned by Karolinska Development AB and Rosetta Capital), Östersjöstiftelsen (The
Foundation for Baltic and East European Studies), and Praktikerinvest PE AB. For
more information, please visit www.modustx.com
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make a
difference to patients' lives while providing an attractive return on investment
to shareholders.
Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes in
the Nordic region. The Company aims to build companies around scientists who are
leaders in their fields, supported by experienced management teams and advisers,
and co-funded by specialist international investors, to provide the greatest
chance of success.
Karolinska Development has established a portfolio of nine companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a
proven track record as company builders and with access to a strong global
network.
For more information, please visit www.karolinskadevelopment.com
Karolinska Development Modus new CEO:
http://hugin.info/143071/R/2097879/794439.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 24.04.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 537754
Anzahl Zeichen: 6080
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 194 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Karolinska Development company Modus Therapeutics announces appointment of Ellen K. Donnelly, Ph.D. as CEO"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
